- Global Market Size.
- Leading players & Growth Strategies.
- Geographic Overview.
Global market size-
According to research report Autotransfusion Systems Market is projected to reach $505 million by 2024, at a CAGR of 5.0%.
Leading Players & Growth Strategies -
Medtronic Plc (Ireland), Becton, Dickinson and Company (US), Zimmer Biomet Holdings, Inc (US), Teleflex Incorporated (US), LivaNova (UK), Fresenius (Germany), Atrium Medical Corporation (Sweden), Haemonetics Corporation (US), SARSTEDT (Germany), Braile Biomédica (Brazil), Redax (Italy), Beijing ZKSK Technology Co (China), and Gen World Medical Devices (India) are some of the leading players.
LivaNova (UK) holds a strong position in the autotransfusion systems market. LivaNova offers its autotransfusion systems through its Cardiovascular segment. The company is recognized as a world leader in autotransfusion due to its experience and commitment to innovative solutions research. Since 2010, XTRA, LivaNova’s latest extraordinarily innovative, intuitive, and powerful ATS system, featuring innovative technological characteristics, ease of use, and powerful performance, has been supporting clinicians in meeting patient blood management goals. XTRA has helped over one million patients reduce allogeneic transfusion risks and shorten their hospital stays.
Haemonetics (US) has successfully positioned itself as a strong player in the autotransfusion systems market. The company has a strong portfolio in providing products for blood, plasma, and whole blood cells. The company’s Cell Saver Elite system provides hospitals with an easy-to-use and reliable way to recover and deliver a patient’s own high-quality blood back during medium to high blood loss procedures, including cardiac, orthopedic, trauma, transplant, vascular, and OBGYN surgeries. On the other hand, in the past three years, the company has not made any significant development in the autotransfusion systems market. This may hamper Haemonetics’ position in the coming years.
For More Details, Download PDF Brochure
Geographic Overview -
The large share of the North American market can mainly be attributed to the high and growing prevalence of target health conditions (cardiovascular, orthopedic, and trauma cases), increasing number of major transplant procedures, scarcity of allogenic blood, preference for autologous blood (due to its advantages), and the strong presence of key market players in the region.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.